Background: One of the key reasons why treating people with diabetes mellitus (DM) and society at large is expensive. To contrast sitagliptin safety and efficiency with glimepiride in Type 2 DM patients who are also being treated with metformin as a background. Methods: From December 2021 to November 2022, this study was carried out at NMCH, Patna, Bihar. Eligible patients were randomly assigned to receive sitagliptin 100 mg and glimepiride 2 mg once daily as an add-on medication for 12 weeks. A pre-populated proforma was filled up with demographic data. All study participants/patients heard advice to keep up a healthy diet and exercise frequently. At week 0 and again at week 12, which is when the trial came to an end, all patients’ HbA1C, FBS, weight, Alanine Aminotransferase (ALT), serum urea, and serum creatinine measurements were obtained. The primary goal was to reach the target HbA1C upper normal level at the end of the study. Results: A total of 120 patients were enrolled in the experiment, with 60 in each group. There were 36 men and 24 women in group B, compared to 32 men and 28 women in group A. Group A utilising sitagliptin demonstrated a statistically significant decline in HbA1C and BMI when compared to the Glimepiride group. (p0.05). Hypoglycemia, diarrhoea, and vomiting were the most frequent adverse reactions in both groups. There was no statistically significant difference in the frequency of occurrence between the two groups (p>0.05). Conclusion: The results of the current research show that sitagliptin, when taken in addition to metformin, improves glycemic control just as effectively as glimepiride and is well tolerated with no obvious side effects. Glimepiride fared worse than sitagliptin, which also had a decreased risk of hypoglycemia. In addition, it was well tolerated and caused weight loss when compared to glimepiride.

Background: One of the key reasons why treating people with diabetes mellitus (DM) and society at large is expensive. To contrast sitagliptin safety and efficiency with glimepiride in Type 2 DM patients who are also being treated with metformin as a background. Methods: From December 2021 to November 2022, this study was carried out at NMCH, Patna, Bihar. Eligible patients were randomly assigned to receive sitagliptin 100 mg and glimepiride 2 mg once daily as an add-on medication for 12 weeks. A pre-populated proforma was filled up with demographic data. All study participants/patients heard advice to keep up a healthy diet and exercise frequently. At week 0 and again at week 12, which is when the trial came to an end, all patients’ HbA1C, FBS, weight, Alanine Aminotransferase (ALT), serum urea, and serum creatinine measurements were obtained. The primary goal was to reach the target HbA1C upper normal level at the end of the study. Results: A total of 120 patients were enrolled in the experiment, with 60 in each group. There were 36 men and 24 women in group B, compared to 32 men and 28 women in group A. Group A utilising sitagliptin demonstrated a statistically significant decline in HbA1C and BMI when compared to the Glimepiride group. (p0.05). Hypoglycemia, diarrhoea, and vomiting were the most frequent adverse reactions in both groups. There was no statistically significant difference in the frequency of occurrence between the two groups (p>0.05). Conclusion: The results of the current research show that sitagliptin, when taken in addition to metformin, improves glycemic control just as effectively as glimepiride and is well tolerated with no obvious side effects. Glimepiride fared worse than sitagliptin, which also had a decreased risk of hypoglycemia. In addition, it was well tolerated and caused weight loss when compared to glimepiride.